Sunday, July 6, 2025 7/6/2025

Tumor-specific activation of transgene expression by Scd3 locus

Award Number: R21CA245602
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/11/2019
PERIOD OF PERFORMANCE END DATE: 11/30/2023

Group Awards By:

View Award Description

Tumor-specific activation of transgene expression by Scd3 locus - Project Summary The development of genetically engineered mouse models (GEMMs) together with the advent of Cre- LoxP technologies and tissue-specific promoters has become excellent tools to assess the functional roles of cancer-associated genes. In recent years, several promoters have been successfully adapted to drive Cre expression specifically within the intestinal epithelium. These promoters have proven useful for manipulating gene expression in normal cells throughout intestinal tract; however, a genetic system that will specifically target intestinal tumors for transgene expression has not yet been developed. Therefore, this exploratory proposal aims to establish a novel mouse model in which the forced expression of a given transgene can be re-introduced through tamoxifen-controlled Cre expression in intestinal tumors. To achieve tumor-specific expression, we will use stearoyl-CoA desaturase (Scd)-3 gene locus as a promoter. We have recently found that Scd3 was consistently up-regulated in intestinal tumors, but not in normal mucosa, suggesting that it may serve as a specific intestinal tumor marker in mice. In Aim 1, we propose to generate Scd3-CreER+/- mice, and Cre activity is validated using a reporter mice. Optimal timing and duration of Cre activity and the efficiency of Cre-Lox recombination will be determined to establish a viable mouse model. In Aim 2, we will then characterize the efficiency of Scd3-CreER system in ApcΔ14/+ tumor model. Finally, in Aim 3, we will extend our analysis to chemically-induced colon cancer model to test the applicability of our Scd3-CreER+/- mice to additional cancer etiologies. We believe that the successful generation of this experimental mouse system will provide a way to test the impact of reactivation of suppressed tumor-associated genes directly within neoplastic tissue, and also enable us to examine the therapeutic effects associated with the functional restoration of the lost genes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$18 )
2024	2021	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Cancer Treatment Research	000	2	4/11/2024	NON-COMPETING CONTINUATION	-$18
														Subtotal = -$18

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Cancer Treatment Research	000	2	11/29/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $230,010 )
2021	2021	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Cancer Treatment Research	001	2	2/1/2021	NON-COMPETING CONTINUATION	$11,501
2021	2021	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Cancer Treatment Research	000	2	11/30/2020	NON-COMPETING CONTINUATION	$218,509
														Subtotal = $230,010

Issue Date FY: 2020 ( Subtotal = $191,675 )
2020	2020	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Cancer Treatment Research	001	1	1/23/2020	NEW	$13,325
2020	2020	UNIVERSITY OF CONNECTICUT	263 FARMINGTON AVE, ASB #3	FARMINGTON	CT	06032	CAPITOL	USA	Cancer Treatment Research	000	1	12/11/2019	NEW	$178,350
														Subtotal = $191,675

Grand Total All Awards = $421,667

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tumor-specific activation of transgene expression by Scd3 locus

Award Number: R21CA245602

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/11/2019

PERIOD OF PERFORMANCE END DATE: 11/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer